Medicinal Immunoglobulin G Products (2020) Show High Infectivity Neutralizing Activity Against Seasonal Influenza Virus Strains Selected for Future Vaccines (2020-2022)

José María Díez; Daniel Casals; Carolina Romero; Rodrigo Gajardo

doi:10.1093/ofid/ofac216

Medicinal Immunoglobulin G Products (2020) Show High Infectivity Neutralizing Activity Against Seasonal Influenza Virus Strains Selected for Future Vaccines (2020-2022)

Open Forum Infect Dis. 2022 Apr 28;9(7):ofac216. doi: 10.1093/ofid/ofac216. eCollection 2022 Jul.

Authors

José María Díez¹, Daniel Casals¹, Carolina Romero¹, Rodrigo Gajardo¹

Affiliation

¹ Immunotherapies Unit, Bioscience Research & Development, Scientific Innovation Office, Grifols, Barcelona, Spain.

Abstract

Immunoglobulin (Ig)G medicinal products manufactured in 2020 were tested for infectivity neutralization and hemagglutination inhibition against World Health Organization-selected influenza strains included in worldwide vaccines 2020-2022. The IgG batches (from US plasma) showed potent activity. Intravenous immunoglobulin could potentially add to therapies for serious influenza cases in immunocompromised patients. Further study is warranted.

Keywords: IgG medicinal products; antibody neutralization; hemagglutination; influenza; vaccination.